摘要
有相当多的数据支持中枢胆碱能系统地在精神分裂症和情感障碍中起作用。目前在获得的增加毒蕈碱受体(CHRMs)结构性数据方面已经取得突破,了解他们在中枢神经系统功能和在合成药物中的作用,可以专门针对每个5-CHRMs。这意味着它适当的被认为是在精神分裂症和情绪障碍的病理生理学上的特定的角色。这篇综述集中对暗示CHRM1和CHRM4水平的改变的数据这篇综述将关注数据的表明CHRM1和CHRM4水平变化及牵连这些受体在精神分裂症的病理生理学数据,及表明CHRM2在情绪障碍作用的数据。会有一个对理解在CNS功能中的CHRM1,2和4的作用的最新进展及这些预测机制如何通过这些受体可以诱导在精神分裂症和情感障碍的普遍症状的选择基准。最后,将对以CHRM1和CHRM4治疗精神分裂症和CHRM2治疗抑郁症症状为靶标的潜在优势和存在问题的进行评论。
关键词: 乙酰胆碱,毒蕈碱受体,精神分裂症,抑郁狂躁型抑郁症,重度抑郁症,神经炎症
Current Molecular Medicine
Title:Possible Involvement of Muscarinic Receptors in Psychiatric Disorders: A Focus on Schizophrenia and Mood Disorders
Volume: 15 Issue: 3
Author(s): B. Dean and E. Scarr
Affiliation:
关键词: 乙酰胆碱,毒蕈碱受体,精神分裂症,抑郁狂躁型抑郁症,重度抑郁症,神经炎症
摘要: A considerable body of data supports a role for the central cholinergic system in the aetiologies of schizophrenia and mood disorders. There have been breakthroughs in gaining structural data on muscarinic receptors (CHRMs), understanding their role in CNS functioning and in synthesising drugs that can specifically target each of the 5 CHRMs. This means it is opportune to consider the role of specific CHRMs in the pathophysiologies of schizophrenia and mood disorders. This review will focus on data suggesting changes in levels of CHRM1 and CHRM4 implicate these receptors in the pathophysiology of schizophrenia whereas data suggest a role for CHRM2 in mood disorders. There will be a selected reference to recent developments in understanding the roles of CHRM1, 2 and 4 in CNS function and how these predict mechanisms by which these receptors could induce the symptoms prevalent in schizophrenia and mood disorders. Finally, there will be comments on the potential advantages and problems in targeting CHRM1 and CHRM4 to treat the symptoms of schizophrenia and CHRM2 to treat the symptom of depression.
Export Options
About this article
Cite this article as:
B. Dean and E. Scarr , Possible Involvement of Muscarinic Receptors in Psychiatric Disorders: A Focus on Schizophrenia and Mood Disorders, Current Molecular Medicine 2015; 15 (3) . https://dx.doi.org/10.2174/1566524015666150330144821
DOI https://dx.doi.org/10.2174/1566524015666150330144821 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibition of Glycogen Synthase Kinase-3 Reverses Tau Hyperphosphorylation Induced by Pin1 Down-Regulation
CNS & Neurological Disorders - Drug Targets Kynurenine Pathway and Disease: An Overview
CNS & Neurological Disorders - Drug Targets Editorial (New Wave from Immunology, Endocrine & Metabolic Agents in Medicinal Chemistr )
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Treatment of Cardiovascular Risk Factors in Women
Current Medicinal Chemistry Patient-Specific Induced Pluripotent Stem Cell Models in Mitochondrial Diseases
Current Stem Cell Research & Therapy A Decrease in the Cellular Phosphodiester to Phosphomonoester Lipid Ratio is Characteristic of HIV-1 Infection
Current HIV Research Visualization of Brain Amyloid and Microglial Activation in Mouse Models of Alzheimers Disease
Current Alzheimer Research Editorial (Thematic Issue: Molecular Targeting for Development of Novel Therapeutic Strategies in Brain Diseases: Myth or Reality?)
CNS & Neurological Disorders - Drug Targets Improvement in Hypertension Management with Pharmacological and Non- Pharmacological Approaches: Current Perspectives
Current Pharmaceutical Design Estrogen Receptor Polymorphisms: Significance to Human Physiology, Disease and Therapy
Recent Patents on DNA & Gene Sequences Metal Protein Attenuating Compounds (MPACs): An Emerging Approach for the Treatment of Neurodegenerative Disorders
Current Bioactive Compounds Long-Acting Antipsychotic Medications
Current Drug Targets Role of Mammalian Target of Rapamycin in Atherosclerosis
Current Molecular Medicine Genetic Susceptibility to Behavioural and Psychological Symptoms in Alzheimer Disease
Current Alzheimer Research Aluminofluoride Complexes: Phosphate Analogues and a Hidden Hazard for Living Organisms
Current Inorganic Chemistry (Discontinued) Lower Frequency of co-Morbid Medical Disorders Related to Poor Impulse Control in Parkinson’s than Alzheimer’s Disease
Current Aging Science Inhibitors of HIV-1 Protease: Current State of the Art 10 Years After their Introduction. From Antiretroviral Drugs to Antifungal, Antibacterial and Antitumor Agents Based on Aspartic Protease Inhibitors
Current Medicinal Chemistry Exploring the Role of Aggregated Proteomes in the Pathogenesis of Alzheimer’s Disease
Current Protein & Peptide Science Meet Our Editorial Board Member:
Cardiovascular & Hematological Agents in Medicinal Chemistry Accelerated Fibrillation of α-Synuclein Induced by the Combined Action of Macromolecular Crowding and Factors Inducing Partial Folding
Current Alzheimer Research